Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTIFY orticumab in post-myocardial infarction coronary inflammation
2025-520464-17-00Phase 2Authorised
- Sponsor
- Abcentra
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease and coronary arteriosclerosis comparing Orticumab with Placebo matching orticumab (2 arms). Primary endpoint: Percent change from baseline in mean fat attenuation index across RCA, LAD, and LCX at 6 months. Planned start Oct 2025; status: authorised.
02
Drugs
orticumab
03
Conditions
atherosclerotic diseasecoronary arteriosclerosis
Beyond the preview
Go deeper on 2025-520464-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520464-17-00.